[Research Advances in CIMAvax-EGF for Non-small-cell Lung Cancer]

Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2018 Jun 28;40(3):411-414. doi: 10.3881/j.issn.1000-503X.2018.03.020.
[Article in Chinese]


The past few years have witnessed rapid advances in the immunotherapies for non-small-cell lung cancer (NSCLC). CIMAvax-EGF is a therapeutic vaccine against lung cancer independently developed by Cuba. It can exert its anti-tumor effect by forming epidermal growth factor (EGF) antibodies to block the binding of EGF to EGF receptor. So far stage both phases Ⅱ and Ⅲ trials have proved its effectiveness and long-term safety,and phases Ⅲ and Ⅳ trials are underway. A deeper understanding of the role of CIMAvax-EGF in NSCLC will accelerate the application of immunotherapy. This article summarizes the recent advances of CIMAvax-EGF R&D and its application in treating NSCLC.

Publication types

  • Review

MeSH terms

  • Antibodies
  • Cancer Vaccines / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Epidermal Growth Factor*
  • ErbB Receptors
  • Humans
  • Lung Neoplasms / drug therapy*


  • Antibodies
  • Cancer Vaccines
  • Epidermal Growth Factor
  • ErbB Receptors